help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on September 27, 2007, doi:10.1164/rccm.200705-732OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200705-732OCv1
177/1/75    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King, T. E.
Right arrow Articles by Raghu, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King, T. E., Jr.
Right arrow Articles by Raghu, G.
American Journal of Respiratory and Critical Care Medicine Vol 177. pp. 75-81, (2008)
© 2008 American Thoracic Society
doi: 10.1164/rccm.200705-732OC

Original Article

BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis

Talmadge E. King, Jr.1, Jürgen Behr2, Kevin K. Brown3, Roland M. du Bois4, Lisa Lancaster5, Joao A. de Andrade6, Gerd Stähler7, Isabelle Leconte8, Sébastien Roux8 and Ganesh Raghu9

1 University of California, San Francisco, San Francisco, California; 2 Medizinische Klinik I, Klinikum Grosshadern der Universität, Munich, Germany; 3 National Jewish Medical and Research Center, Denver, Colorado; 4 National Heart and Lung Institute, London, United Kingdom; 5 Vanderbilt University Medical Center, Nashville, Tennessee; 6 University of Alabama at Birmingham, Birmingham, Alabama; 7 Klinik Löwenstein, Löwenstein, Germany; 8 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; and 9 University of Washington, Seattle, Washington

Correspondence and requests for reprints should be addressed to Talmadge E. King, Jr., M.D., Professor and Chair, Department of Medicine, UCSF, 505 Parnassus Avenue, Room M994, San Francisco, CA 94110. E-mail: tking{at}medicine.ucsf.edu

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment.

Objectives: To determine the effects of bosentan on exercise capacity and time to disease progression in patients with IPF.

Methods: In a double-blind, multicenter trial, patients with IPF were randomized to receive oral bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter, or placebo, for 12 months or longer. The primary efficacy endpoint was change from baseline up to Month 12 in exercise capacity, as measured by a modified six-minute-walk test. Secondary endpoints were time to death or disease progression (worsening pulmonary function tests [PFTs] or acute decompensation), change in PFT scores, and quality of life (QOL) assessed using Short-Form 36 and St. George's Respiratory Questionnaire.

Measurements and Main Results: A total of 158 patients randomly received bosentan (n = 74) or placebo (n = 84). Bosentan showed no superiority over placebo in six-minute-walk distance (6MWD) up to Month 12, the primary efficacy endpoint. A trend in favor of bosentan was observed in the secondary endpoint of time to death or disease progression (hazard ratio [HR], 0.613; 95% confidence interval [CI], 0.328–1.144; P = 0.119), which was more pronounced in a patient subgroup diagnosed using surgical lung biopsy (post hoc analysis; HR, 0.315; 95% CI, 0.126–0.789; P = 0.009). Changes from baseline up to Month 12 in assessments of dyspnea and QOL favored treatment with bosentan. No unexpected adverse events were reported.

Conclusions: Bosentan treatment in patients with IPF did not show superiority over placebo on 6MWD. A trend in delayed time to death or disease progression, and improvement in QOL, was observed with bosentan. The more pronounced treatment effect in patients with biopsy-proven IPF warrants further investigation.

Clinical trial registered with www.clinicaltrials.gov (NCT 00071461).

Key Words: endothelin • idiopathic pulmonary fibrosis • clinical trial • six-minute-walk test • survival


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that affects quality of life. The predominant symptom is progressive dyspnea, which occurs first on exercise and then at rest. Median survival following biopsy-confirmed IPF is less than 3 years.

What This Study Adds to the Field
The BUILD-1 study was a large, randomized, multinational, double-blind, placebo-controlled trial in a well-defined population of patients with IPF. It is the first randomized trial to investigate the effects of an endothelin receptor antagonist in IPF.

 



This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
P. Kulasekaran, C. A. Scavone, D. S. Rogers, D. A. Arenberg, V. J. Thannickal, and J. C. Horowitz
Endothelin-1 and Transforming Growth Factor-{beta}1 Independently Induce Fibroblast Resistance to Apoptosis via AKT Activation
Am. J. Respir. Cell Mol. Biol., October 1, 2009; 41(4): 484 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. B. Ware
Clinical Year in Review I: Interstitial Lung Disease, Pulmonary Vascular Disease, Pulmonary Infections, and Cardiopulmonary Exercise Testing and Pulmonary Rehabilitation
Proceedings of the ATS, September 15, 2009; 6(6): 487 - 493.
[Full Text] [PDF]

Home page
 ChestHome page
G. Raghu and the IPFnet
Improving the Standard of Care for Patients With Idiopathic Pulmonary Fibrosis Requires Participation in Clinical Trials
Chest, August 1, 2009; 136(2): 330 - 333.
[Full Text] [PDF]

Home page
 ChestHome page
V. Cottin and J.-F. Cordier
The Syndrome of Combined Pulmonary Fibrosis and Emphysema
Chest, July 1, 2009; 136(1): 1 - 2.
[Full Text] [PDF]

Home page
 ThoraxHome page
J J Swigris, X Zhou, F S Wamboldt, R du Bois, R Keith, A Fischer, G P Cosgrove, S K Frankel, D Curran-Everett, and K K Brown
Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis
Thorax, July 1, 2009; 64(7): 626 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Tyndall, M. Matucci-Cerinic, and U. Muller-Ladner
Future targets in the management of systemic sclerosis
Rheumatology, June 1, 2009; 48(suppl_3): iii49 - iii53.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. U. Wells, V. Steen, and G. Valentini
Pulmonary complications: one of the most challenging complications of systemic sclerosis
Rheumatology, June 1, 2009; 48(suppl_3): iii40 - iii44.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. J. Rubin
Endothelin and the systemic circulation a therapeutic target worth revisiting?
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1318 - 1319.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Behr and V. J. Thannickal
Update in Diffuse Parenchymal Lung Disease 2008
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 439 - 444.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Stolz and M. Tamm
From the authors
Eur. Respir. J., February 1, 2009; 33(2): 452 - 453.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A. K. Boutou, I. Stanopoulos, G. Pitsiou, and P. Argyropoulou
To the Editors
Eur. Respir. J., February 1, 2009; 33(2): 449 - 450.
[Full Text] [PDF]

Home page
 ACCP Pulmonary Med Brd RevHome page
J. P. Lynch III
Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis
ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686.
[Full Text] [PDF]

Home page
 ERRHome page
K. K. Brown and A. U. Wells
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Eur. Respir. Rev., December 1, 2008; 17(109): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
T M Maher and A U Wells
Optimal treatment for idiopathic pulmonary fibrosis
Thorax, December 1, 2008; 63(12): 1120 - 1121.
[Full Text] [PDF]

Home page
 CirculationHome page
S. Rich and M. Rabinovitch
Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension
Circulation, November 18, 2008; 118(21): 2190 - 2199.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Jackson and C. D. Fell
Etanercept for Idiopathic Pulmonary Fibrosis: Lessons on Clinical Trial Design
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 889 - 891.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. Raghu, K. K. Brown, U. Costabel, V. Cottin, R. M. du Bois, J. A. Lasky, M. Thomeer, J. P. Utz, R. K. Khandker, L. McDermott, et al.
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 948 - 955.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. M. Silver
Endothelin and scleroderma lung disease
Rheumatology, October 1, 2008; 47(suppl_5): v25 - v26.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. U. Wells, J. Behr, and R. Silver
Outcome measures in the lung
Rheumatology, October 1, 2008; 47(suppl_5): v48 - v50.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Behr and J. H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. N. C. Santana, R. A. Kairalla, and C. R. R. Carvalho
Potential Role of Statin Use in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1048 - 1048.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society 		  Work-Life